Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Fundamental Analysis

USA - NASDAQ:SKYE - US83086J2006 - Common Stock

1.3 USD
-0.07 (-5.11%)
Last: 11/14/2025, 8:26:41 PM
1.3 USD
0 (0%)
After Hours: 11/14/2025, 8:26:41 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SKYE. SKYE was compared to 531 industry peers in the Biotechnology industry. While SKYE has a great health rating, there are worries on its profitability. SKYE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SKYE had negative earnings in the past year.
SKYE had a negative operating cash flow in the past year.
In the past 5 years SKYE always reported negative net income.
In the past 5 years SKYE always reported negative operating cash flow.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -81.24%, SKYE is not doing good in the industry: 69.49% of the companies in the same industry are doing better.
The Return On Equity of SKYE (-97.02%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -81.24%
ROE -97.02%
ROIC N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

SKYE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

SKYE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SKYE has more shares outstanding
SKYE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

SKYE has an Altman-Z score of -3.59. This is a bad value and indicates that SKYE is not financially healthy and even has some risk of bankruptcy.
SKYE has a Altman-Z score (-3.59) which is in line with its industry peers.
There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.59
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 6.09 indicates that SKYE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.09, SKYE is in the better half of the industry, outperforming 64.97% of the companies in the same industry.
A Quick Ratio of 6.09 indicates that SKYE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.09, SKYE is doing good in the industry, outperforming 65.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.09
Quick Ratio 6.09
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.67% over the past year.
EPS 1Y (TTM)72.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1245%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SKYE will show a very negative growth in Earnings Per Share. The EPS will decrease by -31.40% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-99.36%
EPS Next 2Y-31.8%
EPS Next 3Y-23.4%
EPS Next 5Y-31.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 50M 100M 150M 200M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SKYE. In the last year negative earnings were reported.
Also next year SKYE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

SKYE's earnings are expected to decrease with -23.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.8%
EPS Next 3Y-23.4%

More info and screens

0

5. Dividend

5.1 Amount

SKYE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SKYE BIOSCIENCE INC

NASDAQ:SKYE (11/14/2025, 8:26:41 PM)

After market: 1.3 0 (0%)

1.3

-0.07 (-5.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners66.08%
Inst Owner Change-4.12%
Ins Owners1.57%
Ins Owner Change0%
Market Cap40.29M
Revenue(TTM)N/A
Net Income(TTM)-42.37M
Analysts81.43
Price Target8.89 (583.85%)
Short Float %7.65%
Short Ratio2.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-371.23%
Min EPS beat(2)-746.82%
Max EPS beat(2)4.35%
EPS beat(4)3
Avg EPS beat(4)-166.09%
Min EPS beat(4)-746.82%
Max EPS beat(4)60.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-41.9%
PT rev (3m)-49.34%
EPS NQ rev (1m)-5.59%
EPS NQ rev (3m)0.17%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)-15.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-3.31
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.24%
ROE -97.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.09
Quick Ratio 6.09
Altman-Z -3.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1245%
EPS Next Y-99.36%
EPS Next 2Y-31.8%
EPS Next 3Y-23.4%
EPS Next 5Y-31.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-169.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.27%
OCF growth 3YN/A
OCF growth 5YN/A

SKYE BIOSCIENCE INC / SKYE FAQ

What is the fundamental rating for SKYE stock?

ChartMill assigns a fundamental rating of 2 / 10 to SKYE.


What is the valuation status for SKYE stock?

ChartMill assigns a valuation rating of 0 / 10 to SKYE BIOSCIENCE INC (SKYE). This can be considered as Overvalued.


What is the profitability of SKYE stock?

SKYE BIOSCIENCE INC (SKYE) has a profitability rating of 0 / 10.


How financially healthy is SKYE BIOSCIENCE INC?

The financial health rating of SKYE BIOSCIENCE INC (SKYE) is 7 / 10.